Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008922 | 1.00 | GPR88 (0.36) | GPR88DPP7SLC15A1DPP8DPP4 | |
| SCHEMBL4011755 | 0.92 | GPR88 (0.39) | GPR88DPP8DPP4DPP9ENPEP | |
| SCHEMBL4006601 | 0.92 | GPR88 (0.39) | GPR88DPP8DPP4DPP9ENPEP | |
| SCHEMBL4014252 | 0.92 | GPR88 (0.39) | GPR88DPP8DPP4DPP9ENPEP | |
| SCHEMBL4010179 | 0.91 | DPP7 (0.44) | GPR88DPP7SLC15A1DPP8DPP4 | |
| SCHEMBL4009484 | 0.91 | DPP7 (0.44) | GPR88DPP7SLC15A1DPP8DPP4 | |
| SCHEMBL4017601 | 0.91 | DPP7 (0.44) | GPR88DPP7SLC15A1DPP8DPP4 | |
| SCHEMBL4011558 | 0.89 | MME (0.37) | GPR88DPP8DPP4DPP9ENPEP | |
| SCHEMBL4004773 | 0.89 | MME (0.37) | GPR88DPP8DPP4DPP9ENPEP | |
| SCHEMBL4010356 | 0.89 | MME (0.37) | GPR88DPP8DPP4DPP9ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | GPR88 767/4885DPP7 1105/4885SLC15A1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.